Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. develops clinical-stage neuroplastogen-derived therapeutics focused on mental health and substance-use disorders. News for CMND centers on CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder, including clinical-trial safety, tolerability, pharmacokinetic and preliminary efficacy updates from a multinational Phase I/IIa study.
Company updates also cover intellectual-property activity for psychedelic and neuroplastogen compounds, including patent applications and licensed development rights tied to PTSD and other mental health disorders. Additional recurring themes include FDA-related clinical communications, data-safety monitoring reviews, clinical-site progress and scientific presentations around MEAI.
Clearmind Medicine (Nasdaq: CMND) will host a live webinar, “Inside MEAI: Exclusive Investigator Q&A with Yale & Johns Hopkins,” on June 10, 2026, from 12:00–1:00 PM EDT.
The event will review early clinical data from the FDA-approved Phase I/IIa multi-center trial of CMND-100, a non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder. Yale’s Dr. Anahita Bassir Nia and Johns Hopkins’ Dr. Jennifer Ellis will discuss findings, while CEO Dr. Adi Zuloff-Shani provides a clinical and corporate update. The webinar, moderated by Shannon Smadella, is free, open to the public, and requires Eventbrite registration.
Clearmind Medicine (Nasdaq: CMND) reported a Japanese patent application publication for MEAI-based compositions targeting depression, expanding its global intellectual property portfolio. MEAI is a non-hallucinogenic molecule intended as an alternative to SSRIs and psychedelic-based therapies.
The company highlights large and growing anxiety, depression, and broader behavioral health markets, including an estimated $16–22.65 billion global anxiety and depression market in 2025. Japan has about 3 million diagnosed MDD cases. Clearmind is also researching MEAI for alcohol use disorder, metabolic disorders such as weight loss, and other mental health indications.
Clearmind Medicine (Nasdaq: CMND) received Johns Hopkins Medicine IRB approval to advance its ongoing Phase I/II CMND-100 trial. The multicenter study in healthy volunteers and Alcohol Use Disorder (AUD) subjects can now proceed to Parts B and C, following successful completion of earlier stages.
Clearmind Medicine (Nasdaq: CMND) approved a 1-for-10 reverse share split of its issued and outstanding common shares, effective May 21, 2026. The action is part of a plan to regain compliance with the Nasdaq Minimum Bid Price Rule.
Issued and outstanding shares will be adjusted from 10,190,337 to approximately 1,019,033, while authorized share capital remains unlimited. No fractional shares will be issued; fractions will be rounded up, and all outstanding options and warrants will be adjusted proportionately.
Clearmind Medicine (Nasdaq: CMND) signed a new research agreement with Yissum to fund a 12‑month preclinical study of MEAI (CMND‑100) with tirzepatide in diet‑induced obese mice.
The study will assess combination and maintenance use in the fast‑growing $50–66B incretin therapeutics market.
Clearmind Medicine (Nasdaq: CMND) announced that CEO Dr. Adi Zuloff-Shani was named a delegate to the Psychedelic Medicine Coalition’s annual federal policy summit held May 14, 2026 at the National Press Club in Washington, D.C.
The summit gathered U.S. federal officials, legislators, researchers, clinicians and biopharma leaders to discuss psychedelic medicine policy. Clearmind is advancing a non-hallucinogenic psychedelic candidate in Phase IIa clinical trials at Johns Hopkins, Yale, and other leading sites.
Clearmind Medicine (Nasdaq: CMND) reported an important milestone in its FDA-approved Phase I/IIa trial of CMND-100 (MEAI) for moderate to severe alcohol use disorder, with 20 participants now treated across all cohorts.
The fourth cohort uses a 160 mg dose, initiated after a positive DSMB recommendation and successful completion of three cohorts (18 participants) that met the primary safety endpoint with no serious adverse events. The multinational, multicenter study assesses safety, tolerability, pharmacokinetics, and preliminary efficacy at leading institutions including Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah Medical Center.
Clearmind Medicine (Nasdaq: CMND) will host a live webinar, “Inside MEAI: New Insights from the CMND-100 Psychedelic Clinical Trial,” on June 10, 2026, 4:00–5:00 PM IDT.
The event will review latest Phase I/IIa CMND-100 data in Alcohol Use Disorder, featuring investigators from Yale and Johns Hopkins, and include corporate updates and a live Q&A.
Clearmind Medicine (Nasdaq: CMND) filed a European patent application on May 5, 2026 for novel, non‑hallucinogenic neuroplastogen-derived compounds targeting PTSD and other mental health disorders. The filing is part of Clearmind’s exclusive worldwide license from Yissum, granting global development, manufacturing, and commercialization rights.
The company said the filing strengthens its intellectual property position in Europe. The announcement cites a 2025 PTSD market valuation of USD 18.5 billion and a projected USD 30.2 billion by 2035. The release also references an April 18, 2026 executive order directing faster federal review of psychedelic-based therapies.
Clearmind Medicine (NASDAQ: CMND) said it is evaluating its lead candidate CMND-100 (MEAI) for potential FDA Breakthrough Therapy Designation based on positive results from its ongoing FDA‑approved Phase I/IIa Alcohol Use Disorder trial. The company has not yet submitted a BTD request and the FDA has not granted designation.
The announcement cites recent policy changes that may accelerate FDA review of certain psychedelic and neuroplastogen therapies.